Polymerase chain reaction

Gilead Appoints Cindy Perettie Executive Vice President of Kite

Retrieved on: 
Tuesday, May 16, 2023

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Cindy Perettie will join the company as Executive Vice President of Kite, a Gilead Company, overseeing the cell therapy business, and will become a member of Gilead’s senior leadership team, effective May 30.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Cindy Perettie will join the company as Executive Vice President of Kite, a Gilead Company, overseeing the cell therapy business, and will become a member of Gilead’s senior leadership team, effective May 30.
  • View the full release here: https://www.businesswire.com/news/home/20230516005214/en/
    Gilead Appoints Cindy Perettie Executive Vice President of Kite (Photo: Business Wire)
    Ms. Perettie brings with her extensive experience in oncology and a commitment to improving patient care.
  • “Cindy has more than 20 years’ experience in scientific and commercial leadership in oncology and has dedicated her career to improving the care of cancer,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead.
  • I believe with the continued focus and commitment of the Kite team we will be able to reach many more cancer patients around the world.”

Applied DNA to Report Second Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, May 11, 2023

Retrieved on: 
Wednesday, May 3, 2023

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release financial results for the three months ended March 31, 2023 after the market close on Thursday, May 11, 2023.

Key Points: 
  • Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release financial results for the three months ended March 31, 2023 after the market close on Thursday, May 11, 2023.
  • The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m.
  • Date & Time: Thursday, May 11 @ 4:30 p.m.
  • The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

Global Genetically Modified Food Safety Testing Market is Expected to Reach $4.8 Billion by 2033: Growing Demand for Genetically Modified Foods Fuels the Sector - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 26, 2023

However, the lack of consistency in testing methods and high testing costs are expected to hinder the market growth.

Key Points: 
  • However, the lack of consistency in testing methods and high testing costs are expected to hinder the market growth.
  • The growing demand for genetically modified foods is expected to fuel market growth during the projected period.
  • The demand for safety testing has grown as a result of the rise in the production and consumption of genetically modified food.
  • The demand for safety testing is growing as more genetically modified crops are produced and consumed.

AlloVir Announces Positive Results Including Long-Term Mortality Data in Phase 2 Posoleucel Multi-Virus Prevention Study in Oral Presentation at EBMT 2023

Retrieved on: 
Wednesday, April 26, 2023

These data were highlighted today in an oral presentation (Abstract OS08-03) at the 49th annual meeting of the European Society for Blood and Marrow Transplantation (EBMT 2023).

Key Points: 
  • These data were highlighted today in an oral presentation (Abstract OS08-03) at the 49th annual meeting of the European Society for Blood and Marrow Transplantation (EBMT 2023).
  • “The data presented today provide further evidence supporting the potential benefits of using posoleucel to prevent viral infection in high-risk allo-HCT patients.
  • "Our global, registrational Phase 3 clinical trial further exploring the potential of posoleucel for multi-virus prevention is well underway and we anticipate data from this registrational study in 2024.
  • More information on the ongoing, global, registrational, Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial of posoleucel for multi-virus prevention can be found on clinicaltrials.gov under the study ID ( NCT05305040 ).

United States Monkeypox Testing Market Outlook & Forecasts 2023-2025: Strong Future Diagnostic Pipeline - Market is Projected to Grow at a Staggering CAGR of 74.26% - ResearchAndMarkets.com

Retrieved on: 
Friday, April 14, 2023

The U.S. monkeypox testing market was valued at USD 5,336.29 thousand in 2022 and is expected to reach USD 91.00 thousand by 2025.

Key Points: 
  • The U.S. monkeypox testing market was valued at USD 5,336.29 thousand in 2022 and is expected to reach USD 91.00 thousand by 2025.
  • From day one of this outbreak, providers had access to a high-quality, FDA-cleared test to detect monkeypox.
  • The regulatory bodies approved the products faster and increased access to monkeypox testing, which further accelerated the U.S. monkeypox testing market.
  • However, this reduced the number of tests conducted in the market, which became a limitation for the U.S. monkeypox testing market.

CENTOGENE Launches NEW CentoGenome®, World’s Most Comprehensive Whole Genome Sequencing Solution for Diagnosis of Rare and Neurodegenerative Diseases

Retrieved on: 
Wednesday, April 12, 2023

and ROSTOCK, Germany and BERLIN, April 12, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the launch of NEW CentoGenome®, an enhanced Next Generation Sequencing (NGS)-based assay.

Key Points: 
  • and ROSTOCK, Germany and BERLIN, April 12, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the launch of NEW CentoGenome®, an enhanced Next Generation Sequencing (NGS)-based assay.
  • Healthcare professionals can leverage NEW CentoGenome to provide more comprehensive diagnostic information, which could accelerate access to potential treatment options.
  • Serving as a first-line test, NEW CentoGenome is the most comprehensive commercially available Whole Genome Sequencing (WGS) test on the market for both rare and neurodegenerative disorders – covering almost all disease-causing variants, including the most relevant repeat expansions associated with neurological diseases, in a single assay.
  • “Building on this expertise, CENTOGENE’s enhanced whole genome sequencing is the leading solution on the market, reflecting the latest advanced technologies and unique insights that can’t be found anywhere else to provide maximized disease coverage.

U.S. Infectious Respiratory Disease Diagnostics Market Report 2023: High Prevalence Of Infectious Respiratory Diseases Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 12, 2023

However, the U.S. infectious respiratory disease diagnostics market is expected to be driven by technological advancements, an increase in the prevalence of infectious respiratory diseases, and high R&D investments by the key players, government, & NGOs to develop novel & innovative products to address the increased market demand.

Key Points: 
  • However, the U.S. infectious respiratory disease diagnostics market is expected to be driven by technological advancements, an increase in the prevalence of infectious respiratory diseases, and high R&D investments by the key players, government, & NGOs to develop novel & innovative products to address the increased market demand.
  • The introduction of innovative products used for disease diagnosis is anticipated to fuel the U.S. respiratory infectious disease market growth.
  • Thus, the increasing incidence of respiratory infections is expected to drive the U.S. infectious respiratory disease diagnostics market during the study period.
  • However, its share is expected to decline to 69.97% by 2030 due to the mass vaccination drives being conducted in the U.S., which, in turn, will reduce the rate of diseases
    Chapter 3 U.S. Infectious Respiratory Disease Diagnostics Market Variables, Trends, And Scope
    3.3.1 High Prevalence Of Infectious Respiratory Diseases In U.S.
    Chapter 4 U.S. Infectious Respiratory Disease Diagnostics Market: Segment Analysis, By Product Type, 2018 - 2030 (USD Million)
    4.2 U.S. Infectious Respiratory Disease Diagnostics Market: Product Type Movement Analysis

Global Biomarker Technologies Market to 2027: Escalating Demand for Early and Effective Diagnosis Drives Growth

Retrieved on: 
Tuesday, April 11, 2023

This, coupled with the escalating demand for early and effective diagnosis, represents one of the key factors positively influencing the market.

Key Points: 
  • This, coupled with the escalating demand for early and effective diagnosis, represents one of the key factors positively influencing the market.
  • Key Questions Answered in This Report:
    How has the global biomarker technologies market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global biomarker technologies market?
  • What is the structure of the global biomarker technologies market and who are the key players?

Molecular Designs releases their new Simplicity™ Gastrointestinal Pathogen Panel

Retrieved on: 
Tuesday, April 11, 2023

BIRMINGHAM, Ala., April 11, 2023 /PRNewswire/ -- Molecular Designs, a developer and manufacturer of molecular infectious disease assays , announces the release of its new Simplicity™ Gastrointestinal Pathogen Panel for the detection of causative agents of gastrointestinal (GI) tract infections.

Key Points: 
  • BIRMINGHAM, Ala., April 11, 2023 /PRNewswire/ -- Molecular Designs, a developer and manufacturer of molecular infectious disease assays , announces the release of its new Simplicity™ Gastrointestinal Pathogen Panel for the detection of causative agents of gastrointestinal (GI) tract infections.
  • The GI panel is a multiplex PCR assay that identifies nucleic acids from 16 different organisms, from a single sample.
  • Molecular Designs assays are manufactured to GMP and ISO 13485:2016 standards and are compatible with most PCR platforms.
  • "Our Simplicity Gastrointestinal Pathogen Panel is available to reference and hospital laboratories," said Robert Crisp , Ph.D., Vice President of Research & Development at Molecular Designs.

FDA Converts to Full Approval Indication for KEYTRUDA® (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors

Retrieved on: 
Wednesday, March 29, 2023

This marks the first full approval for an immunotherapy based on a predictive biomarker, regardless of solid tumor type.

Key Points: 
  • This marks the first full approval for an immunotherapy based on a predictive biomarker, regardless of solid tumor type.
  • Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.
  • Patients were either prospectively enrolled with MSI-H/dMMR tumors (Cohort K) or retrospectively identified in one of 10 solid tumor cohorts (Cohorts A-J).
  • In KEYNOTE-158 and KEYNOTE-164, the median duration of exposure to KEYTRUDA was 6.2 months (range, 1 day to 53.5 months).